Neuroimaging Highlight

Editor: David Pelz

Concomitant Viral and Bacterial Encephalitis after Temozolomide for Glioblastoma

Submitted by: Jenny P. Tsai, Nicolae Petrescu, Warren P. Mason, Leanne K. Casaubon

Can J Neurol Sci. 2014; 41: 84-85

Following resection of a left temporal lobe glioblastoma, a 59-year-old man received radiation therapy with concurrent and adjuvant temozolomide (TMZ). During this time, he was maintained on dexamethasone 4mg daily. His disease remained stable clinically and radiographically on this therapy. (Figure 1)

Four months after radiation therapy, he presented with a one-week history of confusion, hallucinations and fever. A brain computed tomogram scan showed a resection site abscess for which he underwent surgical drainage. Samples obtained at surgery for bacterial culture demonstrated gram positive cocci. A complete blood count revealed mild lymphopenia with a serum lymphocyte count between 600 and 1,000 x 10^6/L, and mildly elevated absolute neutrophil count between 7 and 15 x 10^9/L. Broad-spectrum antibiotic therapy was therefore initiated early for suspected bacterial infection in an immunocompromised patient. However, the patient did not improve clinically and remained stuporous with a best post-operative Glasgow Coma Scale (GCS) never exceeding 7. An electroencephalogram performed three days after surgery showed bilateral anterior temporal periodic lateralizing epileptiform discharges (PLEDs). At that time a brain magnetic resonance imaging (MRI) demonstrated new bilateral temporal, orbito-frontal, and thalamic hyperintensities on T2-weighted sequences (Figure 2).

These findings were suspicious for acute Herpes Simplex virus (HSV) encephalitis, and thus acyclovir was added to his antibiotic regimen. Cerebrospinal fluid (CSF) analysis was positive for herpes simplex virus type 1 by polymerase chain reaction (PCR). Given a high pre-test probability and the known high sensitivity and specificity of CSF PCR analysis for viral meningoencephalitis, the result was concluded as confirmative for HSV-1 encephalitis.1

Despite early broad-spectrum anti-bacterial therapy and immediate initiation of acyclovir following the brain MRI that was suspicious for herpes encephalitis, the patient failed to improve clinically. Follow-up MRI performed three weeks later demonstrated hemorrhagic necrosis of the right anterior temporal lobe and progressive and extensive edema involving adjacent cortex. (Figure 3) Although the patient survived, his functional status was significantly impaired, and no further anticancer therapy was administered. The patient was transferred to palliative care.

Temozolomide is myelosuppressive and causes lymphopenia, with selective CD4+ T-lymphocyte suppression in addition to diminished peripheral CD8+ T-cell and B-cell populations.2

From the Division of Neurology, Department of Medicine, University Health Network-Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.

Received February 25, 2013. Final revisions submitted August 30, 2013.

Correspondence to: Jenny P. Tsai, Toronto Western Hospital, University Health Network, West wing, 5th Floor, 399 Bathurst St., Toronto, Ontario, M5T 2S8, Canada.
Email: jennyp.tsai@utoronto.ca.
Although infectious complications attributed to TMZ alone are rare and carry limited clinical sequelae, caution is warranted in glioma patients who receive this agent. Moreover, many patients with glioblastoma have chronic corticosteroid exposure, which can aggravate the immunosuppressive effects of TMZ by promoting susceptibility to bacterial, viral, fungal and parasitic infections. This predisposition increases with continuous-dosing TMZ regimens, cumulative TMZ dose delivered and duration of treatment. Cases of disseminated herpes zoster, Pneumocystis jiroveci, Cryptococcus, Strongyloidis, and herpes simplex infections, have been reported in patients with gliomas treated with TMZ. Similarly, lymphocytopenia secondary to TMZ may lead to reactivation of cytomegalovirus, resulting in pulmonary, gastrointestinal, and neurological complications, occurring as early as one month after initiation of TMZ therapy. Furthermore, presentation of viral encephalitis may be indolent or mimicking bacterial infection, with a mortality of 20-30% in untreated patients, hence underlining the importance of high clinical caution.

Patients with glioblastoma receiving standard therapy that includes cranial irradiation, temozolomide chemotherapy and chronic exposure to corticosteroids are an immunosuppressed population. Awareness of their susceptibility to a variety of bacterial and viral infections is key to timely diagnosis and initiation of appropriate antimicrobial therapies.

REFERENCES